Marquette University

e-Publications@Marquette
Mathematics, Statistics and Computer Science
Faculty Research and Publications

Mathematics, Statistics and Computer Science,
Department of

6-1-2016

Treatment with ActRIIB-mFc Produces Myofiber
Growth and Improves Lifespan in the Acta1 H40Y
Murine Model of Nemaline Myopathy
Jennifer Tinklenberg
Medical College of Wisconsin

Hui Meng
Medical College of Wisconsin

Lin Yang
University of Florida

Fujun Liu
University of Florida

Raymond G. Hoffmann
Medical College of Wisconsin
See next page for additional authors

NOTICE: this is the author’s version of a work that was accepted for publication in American Journal
of Pathology. Changes resulting from the publishing process, such as peer review, editing, corrections,
structural formatting, and other quality control mechanisms may not be reflected in this document.
Changes may have been made to this work since it was submitted for publication. A definitive version
was subsequently published in American Journal of Pathology, Vol. 186, No. 6 ( June 2016):
1568-1581. DOI. © 2016 Elsevier. Used with permission.

Authors

Jennifer Tinklenberg, Hui Meng, Lin Yang, Fujun Liu, Raymond G. Hoffmann, Mahua Dasgupta, Kenneth P.
Allen, Alan H. Beggs, Edna C. Hardeman, R. Scott Pearsall, Robert Fitts, and Michael W. Lawlor

This article is available at e-Publications@Marquette: https://epublications.marquette.edu/mscs_fac/461

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Treatment with ActRIIB-mFc
Produces Myofiber Growth and
Improves Lifespan in the Acta1
H40Y Murine Model of Nemaline
Myopathy

Jennifer Tinklenberg
Division of Pediatric Pathology, Department of Pathology and
Laboratory Medicine, Medical College of Wisconsin,
Milwaukee, WI
Neuroscience Research Center, Medical College of Wisconsin,
Milwaukee, WI

Hui Meng
Division of Pediatric Pathology, Department of Pathology and
Laboratory Medicine, Medical College of Wisconsin,
Milwaukee, WI

Lin Yang
Department of Biomedical Engineering, University of Florida,
Gainesville, FL

Fujun Liu
Department of Biomedical Engineering, University of Florida,
Gainesville, FL
American Journal of Pathology, Vol 186, No. 6 (June 2016): pg. 1568-1581. DOI. This article is © Elsevier and permission
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

1

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Raymond G. Hoffmann
Quantitative Health Sciences Section, Department of Pediatrics,
Medical College of Wisconsin,
Milwaukee, WI

Mahua Dasgupta
Quantitative Health Sciences Section, Department of Pediatrics,
Medical College of Wisconsin,
Milwaukee, WI

Kenneth P. Allen
Biomedical Resource Center, Office of Research,
Department of Microbiology and Molecular Genetics,
Medical College of Wisconsin,
Milwaukee, WI

Alan H. Beggs
Division of Genetics and Genomics, The Manton Center for
Orphan Disease Research, Boston Children's Hospital,
Harvard Medical School,
Boston, MA

Edna C. Hardeman
Neuromuscular and Regenerative Medicine Unity,
Department of Anatomy, University of New South Wales,
Sydney, Australia

R. Scott Pearsall
Acceleron Pharma Inc.,
Boston, Massachusetts

Robert H. Fitts
Department of Biological Sciences, Marquette University,
Milwaukee, WI

American Journal of Pathology, Vol 186, No. 6 (June 2016): pg. 1568-1581. DOI. This article is © Elsevier and permission
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

2

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Michael W. Lawlor
Division of Pediatric Pathology,
Department of Pathology and Laboratory Medicine,
Medical College of Wisconsin,
Milwaukee, WI
Neuroscience Research Center, Medical College of Wisconsin,
Milwaukee, WI

Nemaline myopathies (NMs) are a group of congenital muscle
diseases caused by mutations in at least 10 genes and associated with
a range of clinical symptoms. NM is defined on muscle biopsy by the
presence of cytoplasmic rod-like structures (nemaline rods) composed
of cytoskeletal material. Myofiber smallness is also found in many
cases of NM and may represent a cause of weakness that can be
counteracted by treatment. We have used i.p. injection of activin type
IIB receptor (ActRIIB)–mFc (an inhibitor of myostatin signaling) to
promote hypertrophy and increase strength in our prior murine work;
we therefore tested whether ActRIIB-mFc could improve weakness in
NM mice through myofiber hypertrophy. We report a study of ActRIIBmFc treatment in the Acta1 H40Y mouse model of NM. Treatment of
Acta1 H40Y mice produced significant increases in body mass, muscle
mass, quadriceps myofiber size, and survival, but other measurements
of strength (forelimb grip strength, ex vivo measurements of
contractile function) did not improve. Our studies also identified that
the complications of urethral obstruction are associated with mortality
in male hemizygote Acta1 H40Y mice. The incidence of urethral
obstruction and histologic evidence of chronic obstruction
(inflammation) were significantly lower in Acta1 H40Y mice that had
been treated with ActRIIB-mFc. ActRIIB-mFc treatment produces a
mild benefit to the disease phenotype in Acta1 H40Y mice.
The nemaline myopathies (NMs) are a clinically and genetically
heterogeneous group of diseases, with a wide range of clinical
phenotypes1 associated with mutations in at least 10 genes (ACTA1,
NEB, TPM3, TPM2, TNNT1, CFL2, KBTBD13, KLHL40, KLHL41, and
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LMOD3).2,3,4,5 With the exception of KBTBD13, the proteins encoded by
all these genes are structural components of (or are associated
with) the sarcomeric thin filament, which is an essential component of
muscle contraction.6,7 The unifying feature of all NM cases is the
presence of characteristic nemaline rods on skeletal muscle biopsy,
which are aggregates of α-actinin and other sarcomeric proteins.8
Although nemaline rods are a critical diagnostic feature of NM, their
abundance, size, and distribution do not correlate well with disease
severity,2 and their direct contribution to the weakness seen in NM is
questionable. Another nonspecific pathologic feature that is seen in
many cases of NM is myofiber smallness (or hypotrophy9), which most
often involves the type 1 myofiber population. This pattern of myofiber
hypotrophy is similar to that seen in other congenital myopathies,
particularly congenital fiber-type disproportion, which has genetic and
phenotypic overlap with some subsets of NM.10,11 Myofiber hypotrophy
represents a potentially reversible pathologic phenotype that has a
known association with muscle strength and should thus be considered
as a therapeutic target for all cases of NM. Currently, there is no
effective treatment for NM.
Because myofiber smallness or suboptimal numbers of
sarcomeres may contribute to weakness in NM, we hypothesized that
induction of myofiber hypertrophy would be of symptomatic benefit in
murine models of NM. Myostatin binds to (and signals through) the
activin type IIB receptor (ActRIIB) to activate the transforming growth
factor-β pathway, which prevents progression through the cell cycle
and down-regulates several key processes related to myofiber
hypertrophy.12,13 Nonfunctional decoys of ActRIIB can be used to
inhibit this negative regulator of myofiber size, leading to myofiber
hypertrophy. In our prior work, we used ActRIIB-mFc, a soluble activin
type IIB receptor, to produce myofiber hypertrophy in wild-type (WT)
mice and in two murine models of X-linked myotubular myopathy
(XLMTM).14,15 In both these studies, the functional effect of
hypertrophy on XLMTM muscle was significantly limited by the
abnormalities of excitation-contraction coupling (ECC) that are also
encountered in this disease. Because physiologic studies performed in
NM mouse models16,17,18,19,20 and myofibers from human patients with
NM21,22,23 do not indicate problems with ECC in NM, we hypothesized
that myostatin/ActRIIB inhibition would produce both hypertrophy and
significant functional benefits in murine models of NM.
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Although a variety of murine models are available for testing,
the Acta1 H40Y mouse represented a good first model for the
evaluation of myostatin inhibition due to its behavioral phenotype and
use in prior treatment studies.18 Acta1 H40Y mice develop moderate
weakness, pathologic features similar to those of NM, and mortality of
approximately half of hemizygote males at 1 to 3 months of age.18 The
pathologic phenotype and clinical course of Acta1 H40Y mice was
improved by crossing them with transgenic mice that produced
myofiber hypertrophy through the overexpression of insulin-like
growth factor-1 or FHL1 (but not c-ski),18 suggesting a benefit from at
least some forms of hypertrophy in these mice. In this study, Acta1
H40Y mice and WT littermates were injected twice per week with 10
mg/kg of ActRIIB-mFc, starting at 2 weeks of age and lasting until
death or 16 weeks of age. Treatment of Acta1 H40Y mice produced
myofiber hypertrophy and improved survival without measurable
increases in limb strength. We also identified an unexpected cause of
death in Acta1 H40Y mice (urinary outlet obstruction) that may
represent a broader-reaching cause of mortality in muscle disease
models. Our studies have found an important new phenotype of
weakness that may affect survival in murine models of neuromuscular
disease, while also revealing that ActRIIB inhibition has the potential
to improve pathologic features and disease course in NM.

Materials and Methods
Live Animal Studies
All studies were performed with approval from the Institutional
Animal Care and Use Committee at The Medical College of Wisconsin
and Marquette University. Genotyping of the Acta1 H40Y mice was
performed as previously described.18 Male WT and Acta1 H40Y mice
were given i.p. injections twice per week with ActRIIB-mFC (also
termed RAP-031; Acceleron Pharma, Cambridge, MA) at a dose of 10
mg/kg or an equivalent volume of Tris-buffered saline (the vehicle
used with ActRIIB-mFc) as previously described14 from 14 days until 4
months of life. Animals were euthanized at 4 months of life because of
a plateau in observable therapeutic effects. Animals were weighed
daily during the treatment period beginning at 2 weeks of age when
the first injection was given. Once the animals were weaned at the age
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of 3 weeks, forelimb grip strength was measured biweekly using a grip
strength meter (Columbus Instruments, Columbus, OH) by placing the
animal on a horizontal grid and allowing it to pull away from the
experimenter using only its forelimbs. The maximum of three
independent measurements, with a 1-minute recovery period between
measurements, was used for subsequent statistical analysis. To
evaluate antigravity hanging performance, animals were tested
biweekly by placing the animal on a rigid mesh surface, inverting the
surface at a height of approximately 40 cm above a cage that
contained at least 3 cm of bedding material, and recording the amount
of time necessary for the animal to fall back into the cage. Animals
that did not fall within 60 seconds were lowered back into their cages.
The maximum of three independent measurements, with a 1-minute
recovery period between measurements, was used for subsequent
statistical analysis. Beginning at 1 month of age, mice were placed in a
circular chamber (49.5 cm) and allowed to freely explore the enclosure
for 10 minutes once a month. The open field tests were videotaped
and analyzed for the total distance traveled by ANY-maze software
version 3.96 (Stoelting, Wood Dale, IL). Also beginning at 1 month of
age, animals were placed on a treadmill moving at 4 to 6 m/min
(Columbus Instruments) every other week and monitored for the
number of falls onto shock bars that occurred during 10 minutes.

Pathologic Evaluation and Tissue Collection
Animals were euthanized with carbon dioxide followed
by cervical dislocation. Animals were photographed after the removal
of the skin from the torso and limbs. The quadriceps, gastrocnemius,
triceps, soleus, extensor digitorum longus (EDL), and diaphragm
muscles were removed, weighed, and frozen in liquid nitrogen–cooled
isopentane.

In Vitro Contractile Properties/Fatigability
Muscle Preparation
Mice were euthanized with carbon dioxide and the EDL and
soleus muscles rapidly removed and placed into a dissecting chamber
containing a room temperature (23°C) Ringer solution (124 nM NaCl, 4
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nM KCl, 1 nM MgCl2, 1 nM KH2PO4, 25 nM NaHCO3, and 2 nM CaCl2
gassed with 95% O2 to 5% CO2, pH 7.40). Muscles were prepared for
study by tying a small loop onto the distal and proximal tendon at the
fiber tendon junction with 4-0 silk thread.24 To determine the
contractile properties and fatigability of the EDL and soleus, each
muscle was transferred to an experimental chamber containing Ringer
solution (95% O2 to 5% CO2) and suspended with the 4-0 loops
between a Cambridge model 352 ergometer (Aurora Scientific, Aurora,
ON) and a fixed post.

Isometric Force Measurement
Each preparation was adjusted to its optimal length at which
maximal twitch and tetanic tension was elicited (resting tension = 2 g)
and isometric contractile properties studied as described previously
and briefly reviewed here.25 The muscles were stimulated along their
entire length with platinum wire electrodes. Peak twitch tension was
elicited with 0.5-ms supermaximal pulse, and contraction time was
measured as the time from the onset of force development to peak
force. Half relaxation time (½RT) was the time required for force to
decay to half of the maximum twitch value. Peak tetanic tension (Po)
was elicited by stimulation at 100 Hz for 500 ms for the soleus and
150 Hz for 200 ms for the EDL. For the twitch and tetanus, the
maximum rate of force development and decay were determined by
measuring the peak slope of the contraction and relaxation,
respectively. The output from the transducer was amplified and
sampled at 3.3 kHz by a Pentium computer using custom-made
software.

Force-Velocity and Power Curves
The force-velocity association was determined, as described
previously.25 At the plateau of peak tetanic contraction, the computer
switched the ergometer from length to force control, and the load on
the muscle was rapidly stepped to maintain three loads less than peak
force. Force was held at each load for 100 ms for the soleus and 40 ms
for the EDL, during which time the change in muscle length was
monitored. The computer calculated the velocity of shortening from
the slope of the length change during the last half of each load step.
This procedure was repeated four times, such that 12 different loads
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were studied for each muscle. Loads were expressed as a percentage
of peak force. Vmax was calculated by the straight-line form of the Hill
equation (P0 − P)/V = P/b + a/b by using loads ≤50% of P0, where P is
force, V is velocity, and a and b are constants with the dimensions of
force and velocity, respectively. A hyperbolic curve was fit to the data
by using the Hill equation (P + a) (V + b) = (P0 + a) b.
Muscle power was calculated from the fitted force-velocity
parameters and the maximum isometric force that was developed
during the experiment.25 Absolute power was defined as the product of
force (in mN) and shortening velocity (ML/s), yielding a final value of
mN·ML−1·s−1.

Muscle Histologic Findings
Cross sections (8 μm) of isopentane-frozen quadriceps muscles
were taken midway down the length of the muscle and stained with
hematoxylin and eosin or Gomori trichrome for evaluation using an
Olympus BX53 microscope with an Olympus DP72 camera and cellSens
standard software (Olympus, Center Valley, PA). Fiber size was
determined through measurements of MinFeret diameter14 because
this measurement offers a myofiber size measurement that is
relatively independent of fiber orientation.26 To evaluate fiber size and
fiber type–specific responses, 8-μm frozen transverse sections of
quadriceps muscle were double-stained with rabbit anti-dystrophin
antibodies (ab15277; 1:100; Abcam, Cambridge, MA) and mouse
monoclonal antibodies against myosin heavy chain type 2b (clone BFF3; 1:50; Developmental Studies Hybridoma Bank, Iowa City, IA).
Secondary antibodies included Alexa Fluor 488–conjugated anti-mouse
IgM (1:400; Sigma-Aldrich, St. Louis, MO) and Alexa Fluor 488–
conjugated anti-rabbit IgG (1:200; Molecular Probes, Carlsbad, CA).
Because of variation in the number and type of oxidative fibers (type 1
and 2a fibers) in mouse muscle, quantitation was performed by
evaluating the type 2b myosin positive (glycolytic) and type 2b myosin
negative (oxidative) populations on a whole slide scan of one
quadriceps muscle from six vehicle-treated WT mice, six ActRIIB-mFc–
treated WT mice, six vehicle-treated Acta1 H40Y mice, and six
ActRIIB-mFc–treated Acta1 H40Y mice. MinFeret diameter was
evaluated using a novel automated technique developed by Dr. Lin
Yang, as we have previously reported.14,15 Glutaraldehyde-fixed strips
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of quadriceps muscle were collected from some mice, and electron
microscopy was performed at the Medical College of Wisconsin's
Electron Microscopy Core Facility.

Organ Histologic Findings
Organs were removed and fixed in 10% neutral buffered
formalin for subsequent paraffin embedding at the Children's Hospital
of Wisconsin Research Institute Histology Core, as previously
described.27,28 The histopathologic findings of all thoracic and
abdominal organs were assessed in a pilot group of four to six animals
per treatment group using hematoxylin and eosin–stained slides. After
recognizing the distribution of genitourinary disease in Acta1 H40Y
males, the pelvic contents of subsequent cohorts of mice were
dissected and histologically evaluated in the sagittal and axial planes.
Because the axial view of the membranous urethra offered the most
consistent view of skeletal muscle features between animals, blocks
revealing axial sections of the membranous urethra at a comparable
site (including the urethra, prostate, striated muscle, and rectum)
were further evaluated by staining for dystrophin (ab15277; Abcam)
or skeletal muscle actin (ab52218; Abcam) to determine the degree of
NM-associated disease in urethral striated muscles and visualized
using biotinylated horse anti-rabbit IgG (BA-1100; Vector
Laboratories, Burlingame, CA). These findings were quantified by
manually counting the number of fibers with actin-positive aggregates
and the total number of fibers in a single medium-powered
(magnification, ×100) field from each of the two urethral striated
muscle fascicles that were reproducibly found along the lateral aspects
of the urethra in axial sections. The skeletal muscle actin antibody that
was used had cross-reactivity with cardiac actin and smooth muscle
actin on testing of this antibody in cardiac and aortic tissue,
respectively.

Hypertrophic Pathway Studies
Muscle tissues from the quadriceps muscle was frozen at
the time of necropsy and stored at −80°C until analysis. Frozen
muscles were crushed in liquid nitrogen and homogenized with lysing
buffer (Cell Signaling Technology, Danvers, MA) containing protease
inhibitor (Roche, Basel, Switzerland) and phosphatase inhibitor
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(Roche). Western blot procedures were performed as previously
described.15,29 Transferred proteins were probed with antibodies
against a variety of antigens. Antibodies recognizing the following
antigens were all obtained from Cell Signaling Technologies (Danvers,
MA): Akt (4691), phospho-Akt (Ser473; 4060), phospho-Akt (Thr308;
2965), p70-S6K (2708), phospho-p70-S6K (Thr421/Ser424; 9204), S6
Ribosomal Protein (2217), phospho-S6 Ribosomal Protein
(Ser240/244; 5364), phospho-eEF2k (Ser366; 3691), and phospho4E-BP1 (Thr37/46; 2855). Other antibodies used for Western blot
studies recognize: myostatin (MAB788; R&D Systems, Minneapolis,
MN), ActRIIB (ab76940; Abcam), and glyceraldehyde-3-phosphate
dehydrogenase (G8795; Sigma-Aldrich) and were visualized using
chemiluminescent horseradish peroxidase antibody detection reagent
(Denville Scientific, Metuchen, NJ). Adequacy of transfer
was determined by Ponceau S staining. Quantification of protein levels
normalized to glyceraldehyde-3-phosphate dehydrogenase was
performed with ImageJ software version 1.48 (NIH, Bethesda, MD;
http://imagej.nih.gov/ij).30 Samples from four animals per treatment
group were used for analysis.

Statistical Analysis
Statistical evaluation was performed using Prism software
version 6.0 (GraphPad Software, Inc., La Jolla, CA) by SAS software
version 9.2 (SAS Institute Inc., Cary, NC) or STATA software version
13.1 (StataCorp, Chicago, IL). For statistical analysis of animal weight,
forelimb grip strength, open field antigravity hanging performance,
and treadmill performance, analyses of variance were performed with
Bonferroni posttests. For muscle weight and mean myofiber diameter
measurements, generalized linear models with Bonferroni posttests
were performed. The survival analysis used Kaplan-Meier with a logrank test. The in vitro contractile property data were analyzed with
multiple unpaired t-tests using Holm-Sidak method and α = 5%. For
statistical analysis of Western blot data, t-tests were used to compare
protein expression among different genotypes or treatments.
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Results
We assessed the effects of ActRIIB-mFc treatment in male
heterozygote Acta1 H40Y mice starting at 14 days of life. Male mice
were used because they reportedly experienced mortality (52% to
61%) as a component of the disease phenotype, whereas mortality
was only reported rarely in female mice (3% to 5%).18 Mice were
dosed twice per week, consistent with our prior studies using ActRIIBmFc, and treatment efficacy was assessed using a variety of
behavioral, physiologic, and pathologic measurements. Study time
points included terminal stage of disease [in animals who reached this
stage before 16 weeks of life (WOL)] or at 16 WOL.

Weight Studies
In animals that received vehicle injections, Acta1 H40Y mice
were distinguishable from WT mice on the basis of weight beginning at
5 WOL (P < 0.05) (Figure 1A). These differences increased and
persisted during the period analyzed (up to 16 weeks of age)
(P < 0.0001). ActRIIB-mFc–treated WT mice had significant weight
gains compared with vehicle-treated WT mice starting at 5 WOL
(P < 0.05), and this difference increased and persisted up to 16 weeks
of age (P < 0.0001). ActRIIB-mFc treatment of Acta1 H40Y mice
resulted in significant animal weight differences compared with
vehicle-treated mutant mice starting at 6 WOL (P < 0.05), but the
relative effect diminished over time as weight differences between
these groups became nonsignificant at 9.5 WOL and persisted as a
nonsignificant trend until the end of the study at 16 WOL.
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Figure 1. Phenotypic findings in VEH- and ActRIIB-mFc–treated mice. A: Total body
weight of VEH- and ActRIIB-mFc –treated mice. B: Forelimb grip force of VEH- and
ActRIIB-mFc–treated mice. C: Open field activity (expressed in meters traveled in 10
minutes) of VEH- and ActRIIB-mFc–treated mice. D: Kaplan-Meier survival curves for
VEH- and ActRIIB-mFc–treated mice. Bars and asterisks denote significant
differences between treatment groups with relevant comparisons. Note that the bar
and asterisk in A illustrate a significant difference between the H40Y/VEH and
H40Y/ActRIIB groups only between 6.5 and 9 weeks of age. The survival comparison
in D between WT/ActRIIB and H40Y/ActRIIB did not reach statistical significance
(P = 0.062). Data are expressed as means ± SEM (A–C). n = 25 for the
WT/VEH group, 19 for the WT/ActRIIB group, 32 for the H40Y/VEH group, and 24 for
the H40Y/ActRIIB group (A–C) and n = 28 for the WT/VEH group, 25 for the
WT/ActRIIB group, 37 for the H40Y/VEH group, and 29 for the H40Y/ActRIIB group
(D). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001. ActRIIB, ActRIIB-mFc treated; VEH,
vehicle; WT, wild type.

Behavioral Studies
Muscle weakness was assessed by evaluating forelimb
grip strength, antigravity hanging performance, open field activity, and
treadmill performance. Interestingly, assays for open field activity and
treadmill performance did not detect significant differences between
vehicle-treated WT and Acta1 H40Y mice at 2 to 16 weeks of age,

American Journal of Pathology, Vol 186, No. 6 (June 2016): pg. 1568-1581. DOI. This article is © Elsevier and permission
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier.

12

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

despite the fact that a considerable number of Acta1 H40Y mice were
dying during this period (Figure 1). Compared with WT animals,
antigravity hanging ability was mildly impaired in Acta1 H40Y mice at
4 to 6.5 WOL (WT/vehicle = 52.75 ± 3.96 seconds versus
H40Y/vehicle = 27.85 ± 4.54 seconds at 4 WOL, P < 0.05) but was
similar to the antigravity hanging performance of WT mice after 6.5
WOL (WT/vehicle = 59.34 ± 0.66 seconds versus H40Y/vehicle
= 51.51 ± 3.66 seconds at 7 WOL). Similarly, treatment of WT and
Acta1 H40Y mice with ActRIIB-mFc did not produce significant changes
in antigravity hanging performance (data not shown), open field
activity (Figure 1C), and treadmill performance (data not shown) at
any time point. There was, however, a clear distinction between the
vehicle-treated WT and Acta1 H40Y mice using forelimb grip strength
testing beginning at 3 WOL and persisting through the end of the
study at 16 WOL (P < 0.0001) (Figure 1B). Treatment of WT mice with
ActRIIB-mFc produced a persistent increase in grip strength starting at
6 WOF (P < 0.01), which is similar in timing and extent to the effects
of ActRIIB-mFc on WT mice in our prior studies.14,15 However,
treatment of Acta1 H40Y mice with ActRIIB-mFc did not significantly
increase forelimb grip strength, although there was a nonsignificant
trend toward slightly increased forelimb grip strength in ActRIIB-mFc–
treated Acta1 H40Y mice.

Survival
Similar to the first published characterization of Acta1 H40Y
mice, we found that vehicle-treated male Acta1 H40Y mice
experienced significant mortality starting at approximately 6 WOL,
with only 30% of vehicle-injected male Acta1 H40Y mice surviving to
the end of the study at 16 WOL (Figure 1D). Interestingly, this
mortality was not accompanied by a decline in behavioral test
performance in most of the mice, which suggested that the cause of
death was not related directly to the inability to move, eat, or breathe.
As previously described,18,31 this mortality was not observed in female
Acta1 H40Y mice, and our study focused on male Acta1 H40Y mice
because survival was a desirable functional end point in a treatment
study. Treatment of male Acta1 H40Y mice with ActRIIB-mFc produced
a significant improvement in survival, including higher overall survival
(55% survival to 16 WOL, P < 0.02). In addition, although none of the
vehicle-treated WT mice died during the study, several ActRIIB-mFc–
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treated WT mice died at late stages of the trial because of apparent
volume overload (indicated by large collections of nonbloody fluid in
the thoracic cavity or both the thoracic and abdominal cavities).
Histologic evaluation of tissue from the lungs of these animals did not
reveal abnormalities. Specific gravity of the abdominal cavity fluid
indicated that it was transudative rather than exudative (data not
shown). This tended to occur in animals that were exceptionally large
and heavy (>35 g) and that were thus receiving large volumes of fluid
with each dose of ActRIIB-mFc.

In Vitro Contractile Properties
Treatment of WT mice with ActRIIB-mFc caused a significant
increase in muscle weight and twitch force in both the soleus and EDL
compared with vehicle-treated WT mice (Table 1). Peak muscle power
was also significantly increased with treatment of WT in both the
soleus (45.6 ± 9.3 versus 23.7 ± 4.1 mN·ML−1·s−1) and EDL
(137.1 ± 32.9 versus 67.8 ± 23.0 mN·ML−1·s−1). The EDL of vehicleinjected Acta1 H40Y mice had a depressed peak tetanic tension, and
this effect was not reversed in the ActRIIB-mFc–treated Acta1 H40Y
mice. The isometric ½RT was significantly prolonged in the soleus of
vehicle-injected Acta1 H40Y mice but not the EDL (P < 0.05). In
addition, the twitch contraction time revealed a trend toward
prolongation (P < 0.1) in the soleus, but statistical evaluation was
limited by the low numbers of vehicle-treated Acta1 H40Y mice
available for this portion of the study (because most mice in this group
died before this 16 WOL evaluation point). ActRIIB-mFc treatment of
the Acta1 H40Y mice partially alleviated the lengthened soleus twitch
duration by preventing prolongation of the ½RT (Table 1). These
slightly differential abnormalities and treatment responses in the EDL
and soleus muscles (which are enriched in glycolytic and oxidative
fibers, respectively) suggest that the capacity for pharmacologically
induced hypertrophy to improve weakness in NM may be partially
dependent on fiber type.
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Table 1. Contractile Properties of the Soleus and EDL in Treated and
Untreated Mice
Property

WT/VEH (n =
4)

WT/ActRIIBmFc (n = 6)

H40Y/VEH (n =
2)

H40Y/ActRIIB-mFc
(n = 5)

Soleus muscle
9.7 ± 1.0

12.9 ± 0.7∗

9.4 ± 0.2

9.5 ± 1.3

31 ± 4

45 ± 4∗

34 ± 2

29 ± 5

Force
(mN/CSA)

35 ± 2

42 ± 4

38 ± 1

34 ± 6

CT (ms)

88 ± 8

79 ± 12

118 ± 10

130 ± 10†

½RT (ms)

79 ± 8

79 ± 12

138 ± 9‡

83 ± 22

Weight (mg)
Twitch data
Force (mN)

Tetanus data
Force (mN)

162 ± 15

195 ± 19

139 ± 35

141 ± 20

Force
(mN/CSA)

187 ± 11

180 ± 18

155 ± 35

181 ± 52

+dP/dt
(mN/s/CSA)

1311 ± 53

1930 ± 150

1279 ± 122

1184 ± 327

−dP/dt
(mN/s/CSA)

−1124 ± 190

−946 ± 192

−537 ± 208

−804 ± 277

0.94 ± 0.11

1.50 ± 0.35

Vmax (mL/s)

0.70 ± 0.01

EDL muscle N = 5

N=6

N=2

N=5

Weight (mg)

11.1 ± 1.3

18.3 ± 2.2∗

8.9 ± 1.7

12.3 ± 1.0

82 ± 7

117 ± 11∗

61 ± 9

59 ± 8†

Force
(mN/CSA)

89 ± 8

83 ± 11

69 ± 3

60 ± 8

CT (ms)

41 ± 2

37 ± 1

45 ± 1

37 ± 1

½RT (ms)

31 ± 3

26 ± 4

25 ± 2

36 ± 4

275 ± 36

339 ± 36

199 ± 1

170 ± 28†

Force
(mN/CSA)

300 ± 44

239 ± 28

232 ± 46

174 ± 27

+dP/dt
(mN/s/CSA)

4896 ± 521

4999 ± 576

4607 ± 33

3852 ± 568

−dP/dt
(mN/s/CSA)

−9977 ± 1659

−7065 ± 1160

−5943 ± 1244

−3674 ± 840

1.87 ± 0.16

2.32 ± 0.25

Twitch data
Force (mN)

Tetanus data
Force (mN)

Vmax (ML/s)

1.40 ± 0.20†

Values are expressed as means ± SEM.
CSA, cross sectional area; CT, contraction time; +dP/dt, maximum rate of force
development; −dP/dt, maximum rate of force decay; EDL, extensor digitorum longus;
½RT, half relaxation time; VEH, vehicle; WT, wild type.
∗P < 0.05 between WT/ActRIIB-mFc and WT/VEH.
†P < 0.05 between Acta1 H40Y/ActRIIB-mFc and WT/ActRIIB-mFc.
‡P < 0.05 between Acta1 H40Y/VEH and WT/VEH.
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Pathologic Evaluation
Evidence of Muscle Growth
Vehicle-injected Acta1 H40Y mice were easily distinguishable
from vehicle-injected WT mice, primarily on the basis of muscle size.
The weights of individual major muscles (quadriceps, triceps,
gastrocnemius) were significantly smaller in vehicle-injected Acta1
H40Y mice compared with vehicle-injected WT mice (P < 0.0001)
(Figure 2A). Muscle weight measurements at 16 WOL found that
ActRIIB-mFc treatment produced significant increases in the weights of
the quadriceps, triceps, and gastrocnemius muscles compared with
vehicle-treated mice of the same genotype (P < 0.001). There was no
gross evidence of selective hypertrophy or atrophy of specific muscles.
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Figure 2. Skeletal muscle histopathologic findings in VEH- and ActRIIB-mFc–treated
mice. A: Individual muscle weights from VEH- and ActRIIB-mFc–treated mice. Bars
and asterisks denote significant (P < 0.05) differences between treatment groups
with relevant comparisons. B: Representative areas of transversely sectioned
quadriceps muscle after sectioning and staining with Gomori trichrome. Acta1 H40Y
mice have pathologic aggregates of purple/red material that corresponds to
aggregates of nemaline rod material. C: Frequency histogram illustrating myofiber size
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distribution in the quadriceps muscles of VEH- and ActRIIB-treated mice. Asterisks
reflect significant differences between treated and untreated animal groups, both in
WT and Acta1 H40Y mice. ∗P < 0.05. Scale bar = 40 μm (B). ActRIIB, ActRIIB-mFc
treated; VEH, vehicle; WT, wild type.

Histologic evaluation of Acta1 H40Y mouse quadriceps muscle
revealed numerous intracellular inclusions that were best visualized on
Gomori trichrome stain, consistent with nemaline rods and with prior
descriptions of muscle disease in this model (Figure 2B).18 Additional
pathologic findings included excessive variation in fiber size and
increased amounts of internally nucleated fibers. None of these
pathologic findings were observed in WT quadriceps muscles. Mean
± SD myofiber size of Acta1 H40Y mice (37.94 ± 0.58 μm) was only
slightly smaller than that observed in WT mice (Table 2), although
frequency histograms of fiber size revealed a difference in fiber size
distributions due to disease (P < 0.05) (Figure 2C). With respect to the
effects of ActRIIB-mFc treatment, treated WT animals had increases in
mean overall fiber size (irrespective of fiber type), which also
corresponded to significant increases seen in both the oxidative and
glycolytic myofiber subpopulations (P < 0.05) (Table 2). The
distribution of myofiber size in WT mice was shifted toward larger
myofiber sizes as a result of ActRIIB-mFc treatment (Figure 2C and
Table 2). Similarly, there was evidence of myofiber hypertrophy in
Acta1 H40Y mice as a result of ActRIIB-mFc treatment, consistent with
the observed increase in muscle weights. Quantitative evaluation of
mean myofiber size revealed a significant increase in Acta1 H40Y
oxidative fiber size with treatment, with nonsignificant trends toward
increased mean fiber size in the glycolytic fiber population and in
myofibers overall (Table 2). The myofiber size distributions of ActRIIBmFc–treated Acta1 H40Y mice were shifted toward larger myofiber
sizes overall (P < 0.05) (Figure 2C). With respect to the presence of
pathologic inclusions (nemaline rod aggregates), manual quantitation
of fibers that contained aggregates of nemaline rods did not identify a
treatment-associated decrease in these structures in the quadriceps
muscle (Figure 2B and Table 2). The structure of these inclusions was
investigated further by electron microscopy using glutaraldehyde-fixed
tissue from the quadriceps muscle, which revealed the presence of
nemaline rods and mitochondrial aggregates, sometimes in association
with myofibrillar disarray (Supplemental Figure S1B). Myofibrillar
inclusions were not observed in the absence of adjacent nemaline rod
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disease, although nemaline rods were sometimes present without
evidence of myofibrillar disarray or mitochondrial aggregation.
Table 2. Quantified Histologic Findings in Treated and Untreated Mice
Finding

WT/VEH

WT/ActRIIBmFc

H40Y/VEH

H40Y/ActRIIB-mFc

Quadriceps muscle
Mean myofiber size (MinFeret diameter, μm)
All fibers

42.70 ± 1.95

55.49 ± 2.04∗

37.94 ± 0.58

44.46 ± 1.93

Oxidative fibers

30.08 ± 1.02

45.24 ± 1.29∗

33.93 ± 0.80

41.63 ± 1.99†

Glycolytic fibers

46.28 ± 2.37

62.90 ± 2.60∗

39.01 ± 0.68

45.76 ± 2.27

1.40 ± 0.50

0.90 ± 0.74

30.20 ± 2.86

35.50 ± 1.97

Pathologic
inclusions (% of
fibers)

Periurethral muscle
Myofiber size
(MinFeret
diameter, μm)

52.25 ± 3.84

53.65 ± 3.90

50.26 ± 4.32

53.67 ± 4.77

Pathologic
inclusions (% of
fibers)

0.00 ± 0.00

0.00 ± 0.00

55.91 ± 5.95

46.2 ± 8.66

Copulatory plugs
(% of animals)
(n/N)

35 (5/14)

76 (10/13)∗

82 (9/11)∗

91 (10/11)

Inflammation (%
of animals) (n/N)

0 (0/14)

0 (0/13)

91 (10/11)†

18 (2/11)

Values are expressed as means ± SEM unless otherwise indicated.
VEH, vehicle; WT, wild type.
∗P < 0.05 between WT/ActRIIB-mFc or Acta1 H40Y/VEH and WT/VEH.
†P < 0.05 between Acta1 H40Y/ActRIIB-mFc and Acta1 H40Y/VEH.

The diaphragm and gastrocnemius muscles were also
qualitatively evaluated histologically (Supplemental Figure S1A), but
these muscles were not evaluated using quantitative methods.
ActRIIB-mFc treatment produced marked hypertrophy of the
diaphragm muscles of both WT and Acta1 H40Y mice, particularly in
glycolytic myofibers. Treatment-induced myofiber hypertrophy was
also apparent in the gastrocnemius muscles of WT mice, but
treatment-induced hypertrophy was less apparent in Acta1 H40Y
gastrocnemius muscles (compared with the WT gastrocnemius and the
Acta1 H40Y quadriceps and diaphragm muscles). Similar to what was
observed in the quadriceps muscle, there did not appear to
be a treatment-related change in pathologic inclusions in the
diaphragm or gastrocnemius muscles.
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Mortality of Acta1 H40Y Mice Is Associated with Bladder Outlet
Obstruction
The Acta1 H40Y mouse model has a curious pattern of mortality
that is primarily restricted to a significant population of male mice at 5
to 13 WOL. This mortality is not observed in Acta1 H40Y females,
implying that there may be critical sex-related differences in
mechanisms leading to mortality in this model. Indeed, further study
of these mice revealed that myofilament function identified sex-related
differences in the contractile performance of the tibialis anterior
muscle, but there was no such dimorphism in the diaphragm, which is
largely responsible for respiratory function.31 Necropsy findings
performed in our study indicate that sex-related survival differences in
Acta1 H40Y mice may primarily be caused by anatomical factors.
Similar to prior studies,18 we have only observed significant mortality
in the 5- to 13-week period in male mice in our Acta1 H40Y colony.
Pathologic examination on necropsy revealed that mortality of Acta1
H40Y mice in our treatment study was typically associated with
marked bladder distension (Figure 3, A and B) and accompanied by
variable degrees of hemorrhage and necrosis in the genital and urinary
tracts. In most cases, areas of induration, hemorrhage, and/or
necrosis were clearly identified in the area of the prostatic urethra.
This phenotype accounted for 34 of 36 Acta1 H40Y mice that died of
disease during this study (23/24 in the Acta1 H40Y/vehicle group and
11/12 in the Acta1 H40Y/ActRIIB-mFc group). Behaviorally, these
animals had difficulty passing urine and had palpable distension of the
bladder, but their ambulation and behavioral test results were not
significantly affected until they were near-terminal. Dilatation of the
bladder and ureters and hydronephrosis were observed in some
animals, consistent with effects secondary to bladder outlet
obstruction. This bladder outlet obstruction was not observed in the
female Acta1 H40Y mice that were being used for breeding in our
colony. Histologically, mice with bladder outlet obstruction typically
had extensive inflammation of the urethra and surrounding tissues,
particularly in the area of the prostate. Urinalysis results revealed
increased numbers of red and white blood cells and increased urine
protein in most cases (data not shown). Necrosis of this tissue and of
tissues further upstream in the genital and urinary tracts was seen to
variable degrees, but necrosis and inflammation of these regions were
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never seen in the absence of obstruction of the urethra. The nature of
the obstruction and the assessment of muscle structure in the urethral
striated muscles were not clearly evaluable because of the extensive
inflammation and tissue damage seen in these animals. However, a
systematic investigation of Acta1 H40Y mice that survived to the 16week study end point was performed, and the genitourinary tracts
were thoroughly examined. Compared with vehicle-injected WT mice,
ActRIIB-mFc–injected WT mice and all Acta1 H40Y mice had a greater
percentage of copulatory plugs (a concretion formed by mice involved
in reproductive behavior) (Figure 3, C and D) in the prostatic
urethra.32,33 Copulatory plugs may be found as an incidental finding
(due to agonal ejection of the plug) or as a legitimate cause of urinary
tract obstruction, and the distinction often relies on the presence of
inflammation as evidence of premortem obstruction. Inflammation of
the genitourinary tract was quantified (in terms of its presence or
absence in adequately sampled areas) as an indicator of significant
premortem urinary tract obstruction, which revealed an absence of
inflammation in WT mice, a very high number [11 (82%) of 13
samples] of vehicle-injected Acta1 H40Y mice with inflammation and
a significantly (P < 0.001) lower number of mice with inflammation in
the ActRIIB-mFc–treated Acta1 H40Y group [2 (18%) of 11 samples]
(Figure 3E). This finding suggests treatment-associated changes to
urethral striated muscle may allow improved copulatory plug ejection
and prevent complications of urinary tract obstruction. Evaluation of
urethral striated muscle (likely involved in the ejection of copulatory
plugs from the urethra) of male Acta1 H40Y mice revealed marked NM,
including actin-positive inclusions in many fibers (Figure 3, F and G).
These inclusions likely corresponded to a combination of nemaline rods
and myofibrillar material, similar to what was seen on electron
microscopy of the quadriceps muscle (Supplemental Figure S1).
Quantitative analysis of the urethral striated muscles revealed that the
mean myofiber size was similar when comparing all four treatment
groups (Table 2), although ActRIIB-mFc treatment produced slight
trends toward increased mean fiber size in both WT and Acta1 H40Y
mice (Figure 3H). Myofiber atrophy (as indicated by small fibers with
angulated cellular contours) was observed in some Acta1 H40Y mice in
association with inflammation, but these samples were not included in
the quantitative analysis because of the likely effect of the
inflammation. Actin-positive cytoplasmic inclusions were only seen in
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Acta1 H40Y (and not WT) mice, and there was a nonsignificant trend
of decreased numbers of these inclusions in the urethral striated
muscles of ActRIIB-mFc Acta1 H40Y mice (Acta1 H40Y/vehicle
= 55.91% ± 5.95%, Acta1 H40Y/ActRIIB = 46.2% ± 8.66%)
(Table 2). Although other organs (including the heart, lungs, brain,
liver, spleen, small intestine, and colon) were evaluated histologically
at necropsy, no pathologic abnormalities were noted in these organs,
including the lungs of treated WT mice that died during the treatment
period.

Figure 3. Genitourinary (GU) tract histopathologic findings in VEH- and ActRIIB-mFc–
treated mice. A and B: Gross and histologic evidence of urethral obstruction leading to
bladder distension, inflammation (asterisk) and necrosis in a subset of Acta1 H40Y
mice that died spontaneously during the trial. C and D: Assessment of copulatory
plugs. C: Axial section of the GU tract of an ActRIIB-mFc–treated Acta1 H40Y mouse
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at 16 weeks of age. A copulatory plug is evident, as is a large amount of urethral
striated muscle surrounding the prostate. There is no evidence of inflammation or
tissue necrosis in this specimen. D: Quantification of mice exhibiting intraurethral
copulatory plugs out of (n) mice per group. E: Quantification of mice exhibiting GU
tissue inflammation out of (n) mice per group. F and G: Immunostaining of urethral
striated muscles for skeletal muscle actin reveals pathologic aggregates of actin
(corresponding to nemaline rod aggregates) in numerous fibers in Acta1 H40Y mice
(G), whereas these aggregates are absent in WT littermates (F). H: Frequency
histogram illustrating myofiber size distribution in urethral striated muscles of VEHand ActRIIB-mFc–treated mice. ∗P < 0.05, ∗∗∗P < 0.001. ActRIIB, ActRIIB-mFc treated;
VEH, vehicle; WT, wild type.

Hypertrophic Pathway Studies
The activation of hypertrophic pathways in WT and Acta1 H40Y
mice was investigated using Western blots. Phosphorylated and
nonphosphorylated constituents of the Akt signaling pathway,
including Akt, P70/S6k, rpS6, 4EBP1, and EEF2k, did not reveal
significant differences with respect to genotype or treatment group
(Figure 4). Levels of myostatin and the activin 2B receptor were both
higher in vehicle-injected Acta1 H40Y mice compared with vehicleinjected WT mice (P < 0.05). Treatment of WT mice with ActRIIB-mFc
produced an increase in myostatin levels (P < 0.05), which is
consistent with the effects of this agent in WT mice in our prior
studies.15 In Acta1 H40Y mice, treatment with ActRIIB-mFc produced a
decrease in myostatin levels (P < 0.05). With respect to ActRIIB
levels, vehicle-injected Acta1 H40Y mice had variable but considerably
higher levels of this protein than vehicle-injected WT animals
(P < 0.02). Treatment with ActRIIB-mFc in both WT and Acta1 H40Y
mice produced nonsignificant trends toward lower ActRIIB levels.
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Figure 4. Expression of proteins related to myofiber growth in VEH- and ActRIIBmFc–treated mice. A: Western blots reveal protein expression of growth-associated
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proteins in the quadriceps muscles of individual WT or Acta1 H40Y mice. B: Quantified
protein expression (normalized to GAPDH expression) for each growth-associated
protein shown in A. Protein extracted from the quadriceps muscle of four 16-week-old
mice per treatment group were tested. ∗P < 0.05, ∗∗P < 0.01. ActRIIB, activin type IIB
receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; VEH, vehicle;
WT, wild type.

Discussion
Myostatin Inhibition as a Therapeutic Strategy in NM
Because of the possible association between myofiber size and
weakness, we hypothesized that the pharmacologic induction of
hypertrophy through myostatin/ActRIIB inhibition would produce
symptomatic benefits in murine NM models. Therapeutic benefits
related to myofiber size could be applicable to patients with NM and
other disorders in which myofiber hypotrophy is a key pathologic
feature, such as congenital fiber-type disproportion. In our prior work
using ActRIIB-mFc as a myostatin inhibition strategy in two murine
models of XLMTM, we observed myofiber hypertrophy that was
functionally limited by abnormalities of ECC that are seen in that
disease.14,15,34,35,36 Because multiple studies of NM models and human
NM tissue have identified intact ECC in NM,16,17,18,19,20,21,22,23 we
expected ActRIIB-mFc treatment to be more effective in murine
models of NM. In the present study, we treated the Acta1 H40Y murine
model of NM with ActRIIB-mFc to determine the potential of this
symptomatic strategy in at least a subset of patients with NM.
ActRIIB-mFc–treated heterozygous male Acta1 H40Y mice experienced
benefits to total-body mass, muscle mass, myofiber size, and survival,
consistent with positive treatment-induced behavioral and pathologic
effects. Surprisingly, we determined that mortality in male Acta1 H40Y
mice is associated with complications of urethral obstruction. Further
study found significant NM pathologic findings in the striated muscles
surrounding the prostate and urethra, and we believe that this
represents a phenotype that is related to muscle weakness.
The genetic heterogeneity of NM poses challenges for the
development of treatments because any gene-specific treatment will
likely only be suitable for a subpopulation of patients with NM. With
respect to nonspecific therapies (such as hypertrophic therapies), it is
currently difficult to predict treatment responsiveness across the NM
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patient population because the degree to which different genetic
causes produce distinct disease states remains unclear. Transgenic
knock-in or knockout mouse models exist for mutations found in the
NEB,20 ACTA1,18,19 TPM3,17 TNNT1,37 CFL2,38 KBTBD13, and KLHL407
genes, and recent studies have explored treatment options in some of
these models. For instance, the pathologic phenotype and clinical
course of Acta1 H40Y mice were improved by crossing them with
transgenic mice that produced myofiber hypertrophy through the
overexpression of insulin-like growth factor-1 or FHL1 (but not c-ski),18
suggesting that induction of myofiber hypertrophy through at least
some mechanisms would be beneficial in these mice. In addition,
although the Tpm3 M9R NM model required a period of disuse to
promote weakness, exercise (and presumably the hypertrophy it
caused) was found to be beneficial in the recovery of this weakness.39
These data suggest that hypertrophic agents (such as myostatin
inhibitors) could provide substantial improvement of pathologic
findings and symptoms in NM. These findings are also supported by
reports of exercise as an effective strategy for minimizing disability in
NM.40 In the current study, ActRIIB-mFc produced muscle hypertrophy
but did not show the clear treatment-associated benefits to forelimb
grip strength or ex vivo contractile function that were observed in
treated WT littermates. The main evidence of therapeutic benefit was
related to improvements in survival. Although this benefit is promising,
further evaluation of myostatin inhibition in NM (in the context of other
Acta1 models and models of other genetic causes of NM) is necessary
to more definitively establish the potential of this therapeutic strategy.

Pathologic Findings Associated with Mortality in this Study
Prior work using the Acta1 H40Y model of NM described
mortality of approximately half of hemizygote males at 1 to 3 months
of age,18 which was presumably related to their skeletal muscle
disease. A similar degree and timing of mortality were observed in the
present study, but we additionally had the opportunity to look for
unexpected causes of death in these mice because we evaluated them
for potential systemic adverse effects. Surprisingly, most mice that
died at 1 to 3 months of age had marked distension of the bladder
with evident acute inflammation and necrosis in the genital and urinary
tracts. This finding was consistent with the complications of
obstruction in the distal urethra with secondary damage that involved
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more proximal regions of the genital and urinary tracts. Histologically,
this was sometimes observed in association with a concretion of
seminal secretions (the so-called copulatory plug) that is a normal
finding in mice but is not a feature of human reproductive function.33
Although this copulatory plug is often observed within the urethra as
an agonal finding and may produce bladder distension artifactually, the
relevance of this finding in the current context is indicated by the
presence of marked genitourinary inflammation in many Acta1 H40Y
mice and the observation of apparent bladder distension and inability
to pass urine in the terminal phase of disease in many Acta1 H40Y
mice in our study. This phenomenon may explain the timing of
mortality at 1 to 3 months (because this corresponds to a period when
male mice reach sexual maturity and would begin producing these
structures) and why female Acta1 H40Y mice do not experience
mortality during this period.18 Pathologic evaluation of the
genitourinary tract revealed that the urethral striated muscle had
significant NM-associated pathologic findings in Acta1 H40Y mice,
including intracellular aggregates that are strongly positive for skeletal
muscle actin. Urethral striated muscle is similar but developmentally
distinct from skeletal muscle,41 and the involvement of this type of
striated muscle (similar to the striated muscle of the esophagus and
perianal region) has not been studied in NM. Although this striated
muscle is structurally and functionally similar to skeletal muscle, it is
developmentally derived from splanchnic mesoderm (instead of being
derived from somites as limb skeletal muscles are).42,43 Our findings
suggest that urethral striated muscle weakness seen in Acta1 H40Y
mice may affect reproductive function in male mice to the extent that
copulatory plugs cannot be passed from the membranous urethra.
Acta1 H40Y mice that were treated with ActRIIB-mFc had similar
numbers of copulatory plugs, but the number of mice with
genitourinary inflammation was markedly decreased. There were
nonsignificant trends toward improved muscle condition in ActRIIBmFc–treated urethral striated muscle (including trends toward larger
fiber size and decreased numbers of fibers with pathologic inclusions).
It is possible that treatment-associated changes in urethral striated
muscle strength and power improved the ability to pass copulatory
plugs through the urethra, thereby improving the survival of ActRIIBmFc–treated Acta1 H40Y mice. The degree to which this phenotype is
observed in other murine models of neuromuscular disease is unclear,
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but it may be useful to include studies of genitourinary anatomy in
characterization or treatment studies of neuromuscular disease.
A recent study of Acta1 H40Y mice has identified distinct causes
of weakness in different muscle types (limb muscles versus
diaphragm),44 and it is possible that a similar difference exists between
limb muscles and urethral striated muscles. Weakness in limb muscles
was primarily due to abnormalities in actin-myosin interactions that
affected cross-bridge cycling, whereas weakness in the diaphragm was
more related to the presence of noncontractile areas in the myofibers.
We found that ActRIIB-mFc induced hypertrophy in Acta1 H40Y mice
in the limb muscles but were unable to find improvements in limb
muscle strength. In vitro studies of muscle contraction, however,
found the treatment to maintain the velocity and power of the soleus
and EDL muscles. However, pathologic findings indicative of urinary
tract obstruction (inflammation of the genitourinary tract and gross
evidence of obstruction) improved as a result of ActRIIB-mFc therapy.
There were trends toward decreased numbers of urethral striated
muscle fibers that contain pathologic aggregates of actin in ActRIIBmFc–treated Acta1 H40Y mice (Table 2). Further study is required to
determine the cause of weakness in Acta1 H40Y urethral striated
muscles, but we posit that ActRIIB-mFc improves function of urethral
striated muscle in a manner that is distinct from the major
mechanisms responsible for weakness in limb muscles. Alternatively, it
is possible that both limb skeletal muscles and urethral striated
muscles have similar causes of weakness, but that the power required
to eject copulatory plugs is considerably less than that required to
produce measurable increases in isometric contraction strength.
With respect to the ActRIIB-mFc–treated WT mice who died late
in the trial period, the presence of large amounts of transudative
thoracic fluid suggests the accumulation of fluid as the result of
injections. Because this study implemented a uniform concentration of
drug across all groups and then based treatment volume on animal
weight, the animals that were the heaviest were recurrently given the
largest treatment volumes. The accumulation of fluid further
contributed to animal weight and compounded the problem, resulting
in marked fluid overload in some of our heaviest animals (all of which
were in the WT/ActRIIB-mFc group). This thoracic fluid overload was
not observed in the other treatment groups. To avoid this complication
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in future trials using ActRIIB-mFc, a higher concentration of the agent
will be used to minimize the volume injected and improve clearance of
fluid.

Hypertrophic Signaling in Acta1 H40Y Mice
Western blots were used in this study to determine the effect of
the Acta1 H40Y mutation on hypertrophic signaling, and the degree
that ActRIIB-mFc therapy changed signaling in these pathways. We
have used this strategy previously to detect disease- and musclespecific signaling abnormalities that were associated with musclespecific treatment effects with ActRIIB-mFc in murine models of Xlinked myotubular myopathy.15 In this study, there was no evidence of
muscle-selective treatment efficacy (with respect to fiber type or
muscle tested) in Acta1 H40Y mice. There were no significant
differences in hypertrophic pathway signaling when comparing vehicleinjected WT and Acta1 H40Y mice, and treatment with ActRIIB-mFc
did not significantly affect the levels of these proteins. There were,
however, significant differences between WT and Acta1 H40Y mice
with respect to the levels of myostatin and the ActRIIB, with vehicleinjected Acta1 H40Y mice having significantly higher levels of both
proteins compared with vehicle-injected WT mice. This higher level of
myostatin in affected mice may provide an explanation for the trend
toward smaller myofibers in Acta1 H40Y mice (and the prior reports of
myofiber smallness in these mice18). However, the degree to which
higher myostatin or ActRIIB levels affect therapeutic effectiveness is
unclear because, as a soluble receptor decoy, ActRIIB-mFc should
prevent the binding of myostatin to the ActRIIB and induction of its
signaling cascade. Overall, though, the key finding here is that there
are no disease-associated abnormalities of hypertrophic signaling in
Acta1 H40Y mice, and thus no expectation that strategies to induce
hypertrophy would be impaired in this model.
Overall, these studies illustrate the first attempt at
antimyostatin treatment in a mouse model of NM, which resulted in a
variety of pathologic improvements and a moderate improvement in
survival for male animals with urethral obstruction. Although muscle
hypertrophy in response to treatment was apparent, there was little to
no evidence of increased strength in limb muscles using a variety of
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assays. Treatment-related improvements in survival were associated
with changes in the degree of genitourinary obstruction and
inflammation in Acta1 H40Y mice, which identified this phenomenon as
a highly relevant phenotype in the assessment of this model. Because
the circumstances of urinary obstruction are presumably due to
weakness and pathologic findings in urethral striated muscles and this
situation is unlikely to be unique to Acta1 H40Y mice, our study also
identifies an important phenotype that should be considered across the
spectrum of murine neuromuscular disease models.
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Supplemental Data

Supplemental Figure S1. Additional pathologic studies of skeletal muscle in wildtype (WT) and Acta1 H40Y mice. A: Gomori trichrome staining of the diaphragm and
gastrocnemius muscles reveal the degree of myofiber hypertrophy and pathologic
inclusion burden seen after vehicle (VEH) or ActRIIB-mFc (ActRIIB) treatment of WT
or Acta1 H40Y mice. B: Electron microscopy (EM) reveals several pathologic
abnormalities in Acta1 H40Y quadriceps muscle, including nemaline rods, and
aggregates of mitochondria (yellow arrows), sometimes surrounded by myofibrillar
disarray. Other areas (right) have nemaline rods/bodies without evidence of
mitochondrial abnormalities or large-scale myofibrillar disorganization. Scale bars: 40
μm (A); 2 μm (B).
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